FDA Advisory Committee recommends approval of Eli Lilly donanemab
SPECIAL REPORT 24.06
US FDA Advisory Committee recommends approval of Eli Lilly donanemab
On June 10, 2024, the US FDA Peripheral and Central Nervous System Drugs Advisory Committee panel recommended approval of Eli Lilly’s donanemab for the treatment of early-stage Alzheimer’s disease.
The panel voted 11-0 that
